Synapse - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma Meeting Abstract

Authors:	Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; Gerdes, H.; Kelsen, D. P.; Ilson, D. H.; Solit, D.; Schultz, N.; Shah, P. M.; Capanu, M.; Hechtman, J. F.; Lamendola-Essel, M.
Abstract Title:	First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
Meeting Title:	44th ESMO Congress (ESMO 2019)
Journal Title:	Annals of Oncology
Volume:	30
Issue:	Suppl. 5
Meeting Dates:	2019 Sep 27-Oct 1
Meeting Location:	Barcelona, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2019-10-01
Start Page:	mdz247.143
Language:	English
ACCESSION:	WOS:000491295502244
PROVIDER:	wos
DOI:	10.1093/annonc/mdz247.143
Notes:	Meeting Abstract: 817P -- Appears on page v313 of the abstract book -- Source: Wos